In the case scenario, Jack, a 47-year-old white male, presents with several health concerns, including stage 2 hypertension, obesity, type 2 diabetes, hyperlipidemia, and tobacco abuse

QUESTION

Please assist in providing pharmacological and non pharmacological plan including rational for this case scenario including references and citation, for each of the 5 diagnosis is under the assessment:

Jack a 47-year-old white male presents to your office for a follow-up visit. He was
seen 2 weeks ago for an upper respiratory infection and noted incidentally to
have a blood pressure of 164/98. He vaguely remembered told in the past that his
B/P was “borderline”. Labs were also done last visit and you are going over the
results with him today. He brings his B/P diary in and it is showing elevated
pressures from 144/94 to 176/96
Today: V/S: Right arm: 172/98; Left arm: 170/96; P 76; resp 16; 70 inches tall
weighs 210
DOB: 3-12-7
Labs from last week: CBC normal; CMP normal; A1C 7.4; TSH normal; Lipids: Total
cholesterol is 250; LDL is 190; HDL 35; Trigs 170
He feels fine, has no complaints.
PMH
Broken arm at age 12.
Hernia repair 10 years ago
No eye examination for about 1.5 years
Meds: zero
Allergies: NKDA
Fam hx:
Father died of stroke at age 69; diabetic
Mother alive at age 69 with HTN, DM
2 sisters ages 45 and 43; the older sister has DM
Social hx: Married. Son age 22 and daughter 20 both healthy. Sedentary job
(Accountant) does not exercise. Smokes 1ppd for 10 years. Has “a couple of beers
every weekend”

Assessment
Stage 2 HTN
Obesity
DM type 2
Hyperlipidemia
Tobacco abuse

Should plug data in cardiac risk into ASCVD risk calculator:
https://tools.acc.org/ASCVD-Risk-Estimator-Plus/ use today’s b/p; he now has
past hx of diabetes; go to view advice
See AACE/ACE Guidelines and ADA guidelines posted in the readings in Module 6.
Also read the attached article

ANSWER

In the case scenario, Jack, a 47-year-old white male, presents with several health concerns, including stage 2 hypertension, obesity, type 2 diabetes, hyperlipidemia, and tobacco abuse. To develop an appropriate plan of care, both pharmacological and non-pharmacological interventions should be considered. The rationale for each intervention will be discussed, supported by relevant references and citations.

Stage 2 Hypertension

Pharmacological Plan: Initiate antihypertensive medication, such as an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), to lower blood pressure levels (AACE/ACE Guidelines). Additionally, a thiazide diuretic can be added if blood pressure remains uncontrolled (ADA Guidelines).

Non-Pharmacological Plan: Encourage lifestyle modifications, including a heart-healthy diet (low sodium, high in fruits, vegetables, and whole grains), regular physical activity, weight loss, and smoking cessation (AACE/ACE Guidelines).

Obesity

Pharmacological Plan: Consider weight loss medications, such as orlistat or liraglutide, in conjunction with lifestyle modifications (AACE/ACE Guidelines). However, the decision to use pharmacotherapy should be based on a comprehensive evaluation of the patient’s obesity-related comorbidities, risk factors, and patient preference.

Non-Pharmacological Plan: Emphasize the importance of dietary changes, calorie restriction, increased physical activity, and behavior modifications. Referral to a registered dietitian can provide tailored nutritional guidance and support (ADA Guidelines).

Type 2 Diabetes

Pharmacological Plan: Initiate metformin as first-line therapy for glycemic control (ADA Guidelines). Additional medication options, such as sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sodium-glucose co-transporter 2 (SGLT-2) inhibitors, may be considered based on individualized patient factors (ADA Guidelines).

Non-Pharmacological Plan: Encourage a comprehensive diabetes self-management education program to improve glycemic control. This includes regular blood glucose monitoring, a balanced diet, physical activity, and weight management (ADA Guidelines).

Hyperlipidemia

Pharmacological Plan: Initiate statin therapy based on the patient’s cardiovascular risk profile, using the ASCVD Risk Estimator Plus tool to determine the 10-year risk (AACE/ACE Guidelines). High-intensity statins, such as atorvastatin or rosuvastatin, are recommended for patients with a history of cardiovascular disease or high-risk features.

Non-Pharmacological Plan: Emphasize lifestyle modifications, including a heart-healthy diet (low in saturated fats and cholesterol), regular exercise, smoking cessation, and weight management. These interventions can help improve lipid profiles and reduce cardiovascular risk (AACE/ACE Guidelines).

Tobacco Abuse

Pharmacological Plan: Consider pharmacotherapy for smoking cessation, such as nicotine replacement therapy (NRT) or bupropion, to assist with smoking cessation efforts (AACE/ACE Guidelines). Combination therapy, such as NRT plus bupropion or varenicline, can enhance quit rates.

Non-Pharmacological Plan: Provide counseling and behavioral interventions to support smoking cessation. Encourage participation in tobacco cessation programs, support groups, and resources available in the community (AACE/ACE Guidelines).

It is essential to consider the patient’s preferences, individual characteristics, and comorbidities when developing a comprehensive plan of care. Regular follow-up appointments and close monitoring of treatment response and adherence are crucial to achieving optimal outcomes.